$15.59
0.251.63%
At Close: -
$15.80
0.211.35%
After Hours: 7:38 PM EDT
15 minutes delayed
Comments
Loading...
Oscar Health
OSCRNYSE
Oscar Health (NYSE:OSCR) Stock, Analyst Ratings, Price Targets, Forecasts
Oscar Health Inc has a consensus price target of $17.48 based on the ratings of 12 analysts. The high is $28 issued by Baird on May 30, 2024. The low is $6 issued by Cowen & Co. on February 14, 2023. The 3 most-recent analyst ratings were released by Piper Sandler, Piper Sandler, and Wells Fargo on July 10, 2024, June 26, 2024, and June 12, 2024, respectively. With an average price target of $25.67 between Piper Sandler, Piper Sandler, and Wells Fargo, there's an implied 62.45% upside for Oscar Health Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Piper Sandler
Wells Fargo
B of A Securities
Baird
Goldman Sachs
1calculated from analyst ratings
Analyst Ratings for Oscar Health
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/10/2024 | Buy Now | 58.23% | Piper Sandler | Jessica Tassan | $25 → $25 | Maintains | Overweight | Get Alert |
| 06/26/2024 | Buy Now | 58.23% | Piper Sandler | Jessica Tassan | → $25 | Initiates | → Overweight | Get Alert |
| 06/12/2024 | Buy Now | 70.89% | Wells Fargo | Stephen Baxter | $24 → $27 | Maintains | Overweight | Get Alert |
| 05/30/2024 | Buy Now | 32.91% | B of A Securities | Adam Ron | $25 → $21 | Downgrade | Buy → Neutral | Get Alert |
| 05/30/2024 | Buy Now | 77.22% | Baird | Michael Ha | → $28 | Initiates | → Outperform | Get Alert |
| 05/20/2024 | Buy Now | 58.23% | B of A Securities | Adam Ron | $22 → $25 | Maintains | Buy | Get Alert |
| 05/09/2024 | Buy Now | 51.9% | Wells Fargo | Stephen Baxter | $20 → $24 | Maintains | Overweight | Get Alert |
| 05/09/2024 | Buy Now | 32.91% | Goldman Sachs | Nathan Rich | $16 → $21 | Maintains | Neutral | Get Alert |
| 03/22/2024 | Buy Now | 26.58% | Raymond James | John Ransom | → $20 | Initiates | → Outperform | Get Alert |
| 02/15/2024 | Buy Now | 26.58% | Wells Fargo | Stephen Baxter | $12 → $20 | Maintains | Overweight | Get Alert |
| 02/09/2024 | Buy Now | 1.27% | Goldman Sachs | Nathan Rich | $8 → $16 | Maintains | Neutral | Get Alert |
| 11/02/2023 | Buy Now | -43.04% | B of A Securities | Adam Ron | $8 → $9 | Upgrade | Neutral → Buy | Get Alert |
| 08/30/2023 | Buy Now | -52.53% | Morgan Stanley | Ricky Goldwasser | $5 → $7.5 | Maintains | Equal-Weight | Get Alert |
| 08/10/2023 | Buy Now | -52.53% | Goldman Sachs | Nathan Rich | $5.5 → $7.5 | Maintains | Neutral | Get Alert |
| 08/09/2023 | Buy Now | -46.2% | Credit Suisse | Jonathan Yong | $7 → $8.5 | Maintains | Outperform | Get Alert |
| 07/14/2023 | Buy Now | -68.35% | Morgan Stanley | Ricky Goldwasser | $5 → $5 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 06/13/2023 | Buy Now | -24.05% | Wells Fargo | Stephen Baxter | $8.5 → $12 | Maintains | Overweight | Get Alert |
| 06/06/2023 | Buy Now | -44.62% | B of A Securities | Kevin Fischbeck | $5.4 → $8.75 | Upgrade | Underperform → Neutral | Get Alert |
| 05/17/2023 | Buy Now | -46.2% | Wells Fargo | Stephen Baxter | $6.75 → $8.5 | Maintains | Overweight | Get Alert |
| 05/10/2023 | Buy Now | -55.7% | Credit Suisse | Jonathan Yong | $6 → $7 | Maintains | Outperform | Get Alert |
| 03/29/2023 | Buy Now | -75.32% | B of A Securities | Kevin Fischbeck | $3.25 → $3.9 | Maintains | Underperform | Get Alert |
| 02/14/2023 | Buy Now | -62.03% | Cowen & Co. | Gary Taylor | $3 → $6 | Maintains | Market Perform | Get Alert |
| 02/14/2023 | Buy Now | -68.35% | Goldman Sachs | Nathan Rich | $3.5 → $5 | Maintains | Neutral | Get Alert |
| 02/10/2023 | Buy Now | -62.03% | Credit Suisse | Jonathan Yong | $7 → $6 | Maintains | Outperform | Get Alert |
| 11/16/2022 | Buy Now | -74.68% | Wells Fargo | Stephen Baxter | → $4 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 11/14/2022 | Buy Now | -68.35% | Morgan Stanley | Ricky Goldwasser | $9 → $5 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 09/01/2022 | Buy Now | -43.04% | Morgan Stanley | Ricky Goldwasser | $12 → $9 | Maintains | Overweight | Get Alert |
| 06/15/2022 | Buy Now | -71.52% | B of A Securities | Kevin Fischbeck | $6 → $4.5 | Downgrade | Neutral → Underperform | Get Alert |
| 06/09/2022 | Buy Now | -24.05% | Morgan Stanley | Ricky Goldwasser | $18 → $12 | Maintains | Overweight | Get Alert |
| 05/26/2022 | Buy Now | -62.03% | B of A Securities | Kevin Fischbeck | $12 → $6 | Downgrade | Buy → Neutral | Get Alert |
| 03/28/2022 | Buy Now | 13.92% | Morgan Stanley | Craig Hettenbach | $20 → $18 | Maintains | Overweight | Get Alert |
| 02/14/2022 | Buy Now | 26.58% | Morgan Stanley | Craig Hettenbach | $19 → $20 | Maintains | Overweight | Get Alert |
| 02/14/2022 | Buy Now | -43.04% | Goldman Sachs | Nathan Rich | $6.5 → $9 | Upgrade | Sell → Neutral | Get Alert |
| 01/07/2022 | Buy Now | -36.71% | Credit Suisse | Jonathan Yong | $21 → $10 | Maintains | Outperform | Get Alert |
| 01/06/2022 | Buy Now | -43.04% | Wells Fargo | Stephen Baxter | → $9 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 12/17/2021 | Buy Now | 20.25% | Morgan Stanley | — | — | Maintains | Overweight | Get Alert |
| 12/14/2021 | Buy Now | -58.86% | Goldman Sachs | Nathan Rich | — | Initiates | → Sell | Get Alert |
| 11/11/2021 | Buy Now | 32.91% | Credit Suisse | Jonathan Yong | — | Maintains | Outperform | Get Alert |
| 08/31/2021 | Buy Now | 64.56% | Morgan Stanley | Craig Hettenbach | — | Maintains | Overweight | Get Alert |
| 08/13/2021 | Buy Now | 89.87% | Wells Fargo | Stephen Baxter | — | Maintains | Overweight | Get Alert |
FAQ
What is the target price for Oscar Health (OSCR) stock?
The latest price target for Oscar Health (NYSE:OSCR) was reported by Piper Sandler on July 10, 2024. The analyst firm set a price target for $25.00 expecting OSCR to rise to within 12 months (a possible 58.23% upside). 15 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Oscar Health (OSCR)?
The latest analyst rating for Oscar Health (NYSE:OSCR) was provided by Piper Sandler, and Oscar Health maintained their overweight rating.
When was the last upgrade for Oscar Health (OSCR)?
The last upgrade for Oscar Health Inc happened on November 2, 2023 when B of A Securities raised their price target to $9. B of A Securities previously had a neutral for Oscar Health Inc.
When was the last downgrade for Oscar Health (OSCR)?
The last downgrade for Oscar Health Inc happened on May 30, 2024 when B of A Securities changed their price target from $25 to $21 for Oscar Health Inc.
When is the next analyst rating going to be posted or updated for Oscar Health (OSCR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Oscar Health, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Oscar Health was filed on July 10, 2024 so you should expect the next rating to be made available sometime around July 10, 2025.
Is the Analyst Rating Oscar Health (OSCR) correct?
While ratings are subjective and will change, the latest Oscar Health (OSCR) rating was a maintained with a price target of $25.00 to $25.00. The current price Oscar Health (OSCR) is trading at is $15.80, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.